

Senate
File
77
-
Introduced


SENATE
FILE
77


BY
ZAUN
and
BOULTON


A
BILL
FOR


An
Act
relating
to
the
regulation
of
medical
cannabidiol,
by
1


altering
the
list
of
debilitating
medical
conditions
and
2


changing
the
definition
of
medical
cannabidiol
under
the
3


medical
cannabidiol
Act.
4


BE
IT
ENACTED
BY
THE
GENERAL
ASSEMBLY
OF
THE
STATE
OF
IOWA:
5


TLSB
1173XS
(2)
88


ss/rh



S.F.
77


Section
1.
Section
124E.2,
subsections
2
and
6,
Code
2019,
1


are
amended
to
read
as
follows:
2


2.
“Debilitating
medical
condition”
means
any
of
the
3


following:
4


a.
Cancer,
if
the
underlying
condition
or
treatment
produces
5


one
or
more
of
the
following:
6


(1)
Severe
or
chronic
pain.
7


(2)
Nausea
or
severe
vomiting.
8


(3)
Cachexia
or
severe
wasting.
9


b.
Multiple
sclerosis
with
severe
and
persistent
muscle


10


spasms


.
11


c.
Seizures,
including
those
characteristic
of
epilepsy.
12


d.
AIDS
or
HIV
as
defined
in
section
141A.1
.
13


e.
Crohn’s
disease.
14


f.
Amyotrophic
lateral
sclerosis.
15


g.
Any
terminal
illness,
with
a
probable
life
expectancy
of
16


under
one
year,
if
the
illness
or
its
treatment
produces
one
or
17


more
of
the
following:
18


(1)
Severe
or
chronic
pain.
19


(2)
Nausea
or
severe
vomiting.
20


(3)
Cachexia
or
severe
wasting.
21


h.
Parkinson’s
disease.
22


i.
Untreatable
pain


Severe
or
chronic
pain
.
23


j.
Any
other
medical
condition
for
which
the
patient’s
24


health
care
practitioner
determines
the
use
of
medical
25


cannabidiol
could
be
medically
beneficial.
26


6.
“Medical
cannabidiol”
means
any
pharmaceutical
27


grade
cannabinoid
found
in
the
plant
Cannabis
sativa
L.
or
28


Cannabis
indica
or
any
other
preparation
thereof
that
has
a
29


tetrahydrocannabinol
level
of
no
more
than
three


thirteen
30


percent
and
that
is
delivered
in
a
form
recommended
by
the
31


medical
cannabidiol
board,
approved
by
the
board
of
medicine,
32


and
adopted
by
the
department
pursuant
to
rule.
33


Sec.
2.
Section
124E.2,
subsection
8,
Code
2019,
is
amended


34


by
striking
the
subsection.
35


-1-


LSB
1173XS
(2)
88


ss/rh
1/
3














S.F.
77


Sec.
3.
Section
124E.3,
subsection
1,
paragraph
a,
Code
1


2019,
is
amended
to
read
as
follows:
2


a.
(1)


Determine,
in
the
health
care
practitioner’s
medical
3


judgment,
whether
the
patient
whom
the
health
care
practitioner
4


has
examined
and
treated
suffers
from
a
debilitating
medical
5


condition
that
qualifies
for
the
use
of
medical
cannabidiol
6


under
this
chapter
,
and
if
so
determined,
provide
the
patient
7


with
a
written
certification
of
that
diagnosis.
8


(2)


If
a
health
care
practitioner
determines
that
the
9


patient
whom
the
health
care
practitioner
has
examined
and
10


treated
suffers
from
a
debilitating
medical
condition
pursuant


11


to
section
124E.2,
subsection
2,
paragraph
“j”
,
that
qualifies
12


for
the
use
of
medical
cannabidiol
under
this
chapter,
the
13


health
care
practitioner’s
written
certification
shall
be
based


14


on
reasonable
medical
evidence,
and
shall
be
made
in
good
15


faith,
in
the
best
interest
of
the
patient,
without
fraudulent
16


intent,
and
with
the
same
reasonable
medical
judgment
and
17


prudence
exercised
according
to
generally
accepted
medical


18


practice.


19


Sec.
4.
Section
124E.5,
subsection
6,
Code
2019,
is
amended
20


to
read
as
follows:
21


6.
The
medical
cannabidiol
board
may
recommend
a
statutory
22


revision
to
the
definition
of
medical
cannabidiol
contained
23


in
this
chapter
that
increases
the
tetrahydrocannabinol
24


level
to
more
than
three


thirteen
percent,
however,
any
such
25


recommendation
shall
be
submitted
to
the
general
assembly
26


during
the
regular
session
of
the
general
assembly
following
27


such
submission.
The
general
assembly
shall
have
the
sole
28


authority
to
revise
the
definition
of
medical
cannabidiol
for
29


purposes
of
this
chapter
.
30


EXPLANATION
31


The
inclusion
of
this
explanation
does
not
constitute
agreement
with
32


the
explanation’s
substance
by
the
members
of
the
general
assembly.
33


This
bill
relates
to
the
regulation
of
medical
cannabidiol.
34


The
bill
amends
the
definition
of
“debilitating
medical
35


-2-


LSB
1173XS
(2)
88


ss/rh
2/
3





















S.F.
77


condition”
under
the
medical
cannabidiol
Act
(Code
chapter
1


124E)
by
removing
the
requirement
that
multiple
sclerosis
be
2


accompanied
by
severe
and
persistent
muscle
spasms,
replacing
3


the
term
“untreatable
pain”
with
“severe
or
chronic
pain”,
and
4


including
any
medical
condition
for
which
a
patient’s
health
5


care
practitioner
determines
the
use
of
medical
cannabidiol
6


could
be
medically
beneficial.
7


The
bill
requires
that
any
certification
made
by
a
health
8


care
practitioner
for
a
patient
for
any
medical
condition
9


not
explicitly
included
on
the
list
of
debilitating
medical
10


conditions
shall
be
made
by
a
health
care
practitioner
pursuant
11


to
reasonable
medical
evidence,
in
good
faith,
in
the
best
12


interest
of
the
patient,
without
fraudulent
intent,
and
with
13


the
same
reasonable
medical
judgment
and
prudence
exercised
14


according
to
generally
accepted
medical
practice.
Under
15


current
law,
a
health
care
practitioner
may
only
issue
a
16


written
certification
for
a
debilitating
medical
condition
17


explicitly
included
on
the
list
of
debilitating
medical
18


conditions.
A
written
certification
may
be
renewed
on
an
19


annual
basis
if
the
health
care
practitioner
determines
that
20


the
patient
continues
to
suffer
from
the
debilitating
medical
21


condition.
22


The
bill
alters
the
definition
of
medical
cannabidiol
by
23


increasing
the
allowable
tetrahydrocannabinol
(THC)
level
in
24


medical
cannabidiol
from
no
more
than
3
percent
to
no
more
25


than
13
percent.
The
medical
cannabidiol
board
retains
the
26


authority
to
recommend
increasing
the
allowable
THC
level.
27


-3-


LSB
1173XS
(2)
88


ss/rh
3/
3

